Manufactures enzymes for nutrition, food processing and industrial processing
1989
Thane (India)
Public
Advanced Enzyme Technologies Ltd. (AETL) is a research-driven company that develops, manufactures, and markets enzymes and probiotics. Founded in 1989 and based in Thane, India, the company went public on July 21, 2016. AETL is among the top 15 global enzyme companies and has the highest market share in India.
Overview:
AETL has a diverse product portfolio of over 68 enzymes and 400 proprietary products, serving more than 700 clients across 45 countries.
The company operates in four main segments: Human Nutrition, Animal Nutrition, Industrial Bio-Processing, and Specialized Manufacturing.
AETL has nine manufacturing facilities globally, including four in India, one in the US, and four in other regions. It also has seven R&D centers.
The company aims to offer continuous solutions and advocates for enzyme-based processes as a sustainable alternative to traditional methods.
Business Segments:
Human Nutrition: AETL provides enzyme products, probiotics, and customized enzyme solutions to pharmaceutical and nutraceutical companies. Focus areas in R&D include sugar management and weight loss.
Animal Nutrition: AETL offers solutions to enhance nutrition for animals.
Industrial Bio-Processing: This segment has shown good growth, with a significant rise on a year-on-year basis.
Specialized Manufacturing: AETL uses its facilities for various industries, including poultry, cosmetics, and other specialty products.
Manufacturing and R&D:
A new manufacturing facility near Indore has trebled the company's fermentation capacity to 400 m3. The facility is designed to allow for further expansion.
AETL is an R&D-focused company, investing 4-5% of sales in R&D. It has filed 17 patents so far and has been awarded 9.
Subsidiaries and Management:
AETL has a group of companies, including Specialty Enzymes & Probiotics, AST Enzymes, and Dynamic Enzymes Inc USA.
Key management personnel include Mr. Mukund Kabra, Mr. Beni Prasad Rauka, Dr. Anil Kumar Gupta, and Mr. Dipak Roda.
-
2
Undisclosed, Post IPO
as of September 10, 2020
-
as of N/A
-
as of N/A
Orbimed
and 2 more300
Ace Blend
Public
Date | Round Name | Amount | Valuation | Revenue | Revenue Multiple | Investors |
---|---|---|---|---|---|---|
September 10, 2020 | Post IPO | Undisclosed | Nalanda Capital |